**Epidemic**

**Prevalence of Hepatitis B**
- General Population: 0.9%
- Blood Donors: 0.8%
- Antenatal Clients: 0.5%
- MSM: 3.5%
- PWID: 6%
- CSW: 0%
- PLHIV: 0%

**Prevalence of Hepatitis C**
- General Population: 0.6%
- Blood Donors: 0.5%
- Antenatal Clients: 0%
- MSM: 19%
- PWID: 42%
- CSW: 3.7%
- PLHIV: 0%


*Blue – representative sample; **Red – non-representative sample; MSM – men who have sex with men and PWID – people who inject drugs

**Policies**

**Hepatitis B vaccine**
- Birth dose of Hep B vaccine - YES
- Hep B immunization included in routine infant immunization schedule - YES
- Vaccination for HCWs - YES
- Vaccination for high risk groups (key populations) - NA

**Blood & Injection safety**
- Donated blood screened for Hep B & Hep C - YES
- Use of RUP syringes - NA
- Needle and syringe distribution program for PWID - YES

**Hepatitis testing**
- Is there official guidance for diagnosing HBV - Planned
- Is there official guidance for diagnosing HCV - YES

**Access to medicines**

| Availability of medicines for Hep B treatment | YES |
| Annual cost for Hep B treatment | $360 |
| Availability of DAAs for Hep C treatment | YES |
| Annual cost for Hep C treatment | $1500 |

**Health sector response**

**National Plan for viral hepatitis** Planned

- Coverage of 3-dose Hep B vaccine schedule: 92% (2014)
- Coverage of Hep B vaccine for newborns: 92%
- Needles and syringes distributed per PWID in the last one year: 25

*Source: Country survey*

**Mortality**

**Nepal**
- Acute Hepatitis B: 23%
- Liver cancer HBV: 5%
- Cirrhosis HBV: 72%

**Nepal**
- Acute Hepatitis C: 3%
- Liver cancer HCV: 7%
- Cirrhosis HCV: 90%

*Source: WHO GHE, 2016*

**Healthcare utilization**

- Estimate of facilities offering serological testing (HBsAg) for HBV: >100
- Estimate of facilities offering nucleic acid testing (NAT) for HBV: 1
- Estimate of facilities offering serological testing (Anti-HCV) for HCV: >100
- Estimate of facilities offering nucleic acid testing (NAT) for HCV: 1

*Source: Country survey*